Clinical trials: SARS
SARS-CoV-2 Infection, Active Immunization
Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately…
- Conditions
- SARS-CoV-2 Infection, Active Immunization, Immune Response, Immunosuppression
- Trial name
- DIA-Vacc (NCT04799808)
- Where
- Germany
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
COVID-19
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Since December 2019, the emergence of a new coronavirus named SARS-Cov-2 in the city of Wuhan in China has been responsible for a major epidemic of respiratory infections, including severe pneumonia.
- Trial name
- COVIDAXIS (NCT04328285)
- Testing
- Hydroxychloroquine, Lopinavir and ritonavir
- Where
- 9 sites in France
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
COVID-19 Infection
Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)
The Investigators propose a multi-center, observational, longitudinal, cohort study of the serology and wellness of HCWs over a year of the COVID-19 pandemic.
- Trial name
- CONSERVE-HCW (NCT04595175)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Brian Tiffany, MD
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID -19
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults.
- Trial name
- NCT07703475
- Testing
- RVX-sCPD9
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID 19, Respiratory Synctial Virus
COMMUNITY - the COVID-19 Immunity Study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients.
- Conditions
- COVID 19, Respiratory Synctial Virus, Influenza Virus, SARS-CoV-2 Virus
- Trial name
- COMMUNITY (NCT06784739)
- Testing
- Blood sampling, Mucosal sampling, PCR-test
- Where
- 2 sites in Sweden
- Volunteers
- 2,420 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Covid-19, Protection Against COVID-19
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan.
- Trial name
- NCT04537949
- Testing
- BNT162b3
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID, Terminal Renal Insufficiency
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19
Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020
- Trial name
- COVCKD (NCT04367714)
- Where
- Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region MidtJylland Denmark
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of…
- Trial name
- NCT05216484
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Covid19, Corona Virus Infection
T Cells Response to SARS COV 2 Peptides
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral…
- Trial name
- NCT04573348
- Testing
- Savicell's ImmunoBiopsy™
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Savicell Diagnostics Ltd
Occupational Exposure to SARS-CoV-2, COVID-19
COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers
The COVID-19 CHAMPS Study will obtain data on the physical and mental health and well-being of workers potentially exposed to the SARS-CoV-2 virus in the course of their duties.
- Trial name
- CHAMPS (NCT04370821)
- Where
- United States
- Volunteers
- 2,600 people, healthy volunteers welcome
- Sponsor
- Villanova University
Covid19, SARS-CoV-2
Changes in Cellular Immune Profile During COVID-19 Infection
Clinical specimens are collected from individuals either recovered from or with active SARS-CoV-2 infection to support process and analytical development for a potential cell-based immunotherapy in preclinical research…
- Trial name
- NCT04470999
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Serhat Gumrukcu, MD PhD
COVID-19
Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the safety and immnunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above.
- Trial name
- NCT05552573
- Testing
- low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co.
- Trial name
- NCT04884685
- Testing
- SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients.
- Trial name
- SCLC (NCT06291870)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Coronavirus, Coronavirus Infection
BCG Vaccine for Health Care Workers as Defense Against COVID 19
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW).
- Conditions
- Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
- Trial name
- BADAS (NCT04348370)
- Testing
- BCG Vaccine
- Where
- 6 sites in United States
- Volunteers
- 659 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
COVID-19
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult…
- Trial name
- NCT06068569
- Testing
- GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID
Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs.
- Trial name
- Chloroquine UN (NCT04346329)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Severe Acute Respiratory Syndrome
Contamination During Removal of Two Different Personal Protective Systems
Highly communicable and virulent diseases, the ongoing threat of emerging infectious diseases, and the prospect of bio-terrorism have become part of the new reality for health care workers.
- Trial name
- NCT00150475
- Testing
- Powered Air purifying respirator
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Queen's University
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.